The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Open accessAbstract
Paclitaxel is a broad‐spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent‐induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half‐life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · cited 1×
“The mortality of cancer is reported more in men than in women, especially for lung, colorectal, and stomach cancers [171, 172].”
BackgroundMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Newman, D. J., & Cragg, G. M. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01285 · Cited by 7,015
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Cited by
Dhyani, P., Quispe, C., Sharma, E., Bahukhandi, A., Sati, P., Attri, D. C., Szopa, A., Sharifi-Rad, J., Docea, A. O., Mardare, I., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02624-9 · Cited by 483
Self-citationDiosgenin: An Updated Pharmacological Review and Therapeutic Perspectives
Semwal, P., Painuli, S., Abu-Izneid, T., Rauf, A., Sharma, A., Daştan, S. D., Kumar, M., Alshehri, M. M., Taheri, Y., Das, R., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1035441 · Cited by 195
Self-citationKitic, D., Miladinovic, B., Randjelovic, M., Szopa, A., Sharifi-Rad, J., Calina, D., & Seidel, V. (2022) · Plants · doi:10.3390/plants11141885 · Cited by 96
Self-citationMyricetin: Targeting signaling networks in cancer and its implication in chemotherapy
Javed, Z., Khan, K., Herrera-Bravo, J., Naeem, S., Iqbal, M. J., Raza, Q., Sadia, H., Raza, S., Bhinder, M., Calina, D., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02663-2 · Cited by 93
Self-citationTherapeutic Applications of Curcumin in Diabetes: A Review and Perspective
Quispe, C., Herrera-Bravo, J., Javed, Z., Khan, K., Raza, S., Gulsunoglu-Konuskan, Z., Daştan, S. D., Sytar, O., Martorell, M., Sharifi-Rad, J., et al. (2022) · BioMed Research International · doi:10.1155/2022/1375892 · Cited by 92
Self-citation
Metadata
- Authors
- Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., Živković, J., Cruz-Martins, N., Klimek-Szczykutowicz, M., Ekiert, H., Choudhary, M. I., Ayatollahi, S. A., Tynybekov, B., Kobarfard, F., Muntean, A. C., Grozea, I., Daştan, S. D., Butnariu, M., Szopa, A., & Calina, D.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 2021
- Issue
- 1
- Pages
- 3687700-3687700
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W3205724362
- Cited by
- 298
- References
- 217
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy. https://app.cochat.ai/papers/10.1155/2021/3687700
- The paper
- Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., Živković, J., Cruz-Martins, N., Klimek-Szczykutowicz, M., Ekiert, H., Choudhary, M. I., Ayatollahi, S. A., Tynybekov, B., Kobarfard, F., Muntean, A. C., . . . Calina, D. (2021). Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2021/3687700
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
